Simultaneous quantification of the CYP2D6 substrate yohimbine, its metabolite 11-OH-yohimbine, and the CYP2D6 inhibitor paroxetine in human plasma
We developed and validated a human plasma LC-MS/MS assay according to FDA guidelines to determine the impact of the CYP2D6 inhibitor paroxetine on the pharmacokinetics of the assumed specific CYP2D6 substrate yohimbine. Yohimbine, its main metabolite 11-OH-yohimbine, and paroxetine were quantified u...
Gespeichert in:
| Hauptverfasser: | , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
4 November 2019
|
| In: |
Analytical methods
Year: 2019, Jahrgang: 11, Heft: 47, Pages: 5976-5983 |
| ISSN: | 1759-9679 |
| DOI: | 10.1039/C9AY01715A |
| Online-Zugang: | Verlag, Volltext: https://doi.org/10.1039/C9AY01715A Verlag, Volltext: https://pubs.rsc.org/en/content/articlelanding/2019/ay/c9ay01715a 
|
| Verfasserangaben: | Manuela Vay, Gisela Skopp, Gerd Mikus and Jürgen Burhenne |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1687134588 | ||
| 003 | DE-627 | ||
| 005 | 20230427090059.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 200110s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1039/C9AY01715A |2 doi | |
| 035 | |a (DE-627)1687134588 | ||
| 035 | |a (DE-599)KXP1687134588 | ||
| 035 | |a (OCoLC)1341297648 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Vay, Manuela |d 1990- |e VerfasserIn |0 (DE-588)1181123127 |0 (DE-627)1662506872 |4 aut | |
| 245 | 1 | 0 | |a Simultaneous quantification of the CYP2D6 substrate yohimbine, its metabolite 11-OH-yohimbine, and the CYP2D6 inhibitor paroxetine in human plasma |c Manuela Vay, Gisela Skopp, Gerd Mikus and Jürgen Burhenne |
| 264 | 1 | |c 4 November 2019 | |
| 300 | |a 8 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 10.01.2019 | ||
| 520 | |a We developed and validated a human plasma LC-MS/MS assay according to FDA guidelines to determine the impact of the CYP2D6 inhibitor paroxetine on the pharmacokinetics of the assumed specific CYP2D6 substrate yohimbine. Yohimbine, its main metabolite 11-OH-yohimbine, and paroxetine were quantified using plasma (100 μL) and liquid-liquid extraction for sample preparation. Analytes were separated with a Phenomenex Luna C18 3 μm LC column using a gradient consisting of ammonium acetate (5 mM), acetic acid, and acetonitrile. Tandem mass spectrometry detection was performed using positive electrospray ionization and selective reaction monitoring utilizing 13C- and deuterium-labeled internal standards in the calibration range from 0.5 to 500 ng mL−1. Accuracy at the lower limit of quantification of 0.5 ng mL−1 was <19% with the corresponding precision being <16%. Within-batch and batch-to-batch accuracies were <14% with the corresponding precision being <12%. Extraction recoveries ranged between 75 and 113% for all analytes. This assay was used to simultaneously quantify plasma concentrations of yohimbine, its metabolite, and paroxetine after oral administration of 5 mg yohimbine solely and in combination with a three-day intake of 20 mg paroxetine to a healthy individual. This enabled the investigation of yohimbine pharmacokinetics and its CYP2D6 dependent metabolization in correlation with plasma exposure to the CYP2D6 inhibitor paroxetine, resulting in doubled maximum concentration, a tenfold increase of AUC and fourfold prolonged elimination half-life. | ||
| 700 | 1 | |a Skopp, Gisela |d 1951- |e VerfasserIn |0 (DE-588)1060738538 |0 (DE-627)800969413 |0 (DE-576)164452346 |4 aut | |
| 700 | 1 | |a Mikus, Gerd |e VerfasserIn |0 (DE-588)110903137 |0 (DE-627)691097941 |0 (DE-576)336988710 |4 aut | |
| 700 | 1 | |a Burhenne, Jürgen |d 1963- |e VerfasserIn |0 (DE-588)1034228889 |0 (DE-627)745126987 |0 (DE-576)381858197 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Analytical methods |d Cambridge : RSC Publ., 2009 |g 11(2019), 47, Seite 5976-5983 |h Online-Ressource |w (DE-627)609401521 |w (DE-600)2515210-5 |w (DE-576)314872167 |x 1759-9679 |7 nnas |a Simultaneous quantification of the CYP2D6 substrate yohimbine, its metabolite 11-OH-yohimbine, and the CYP2D6 inhibitor paroxetine in human plasma |
| 773 | 1 | 8 | |g volume:11 |g year:2019 |g number:47 |g pages:5976-5983 |g extent:8 |a Simultaneous quantification of the CYP2D6 substrate yohimbine, its metabolite 11-OH-yohimbine, and the CYP2D6 inhibitor paroxetine in human plasma |
| 856 | 4 | 0 | |u https://doi.org/10.1039/C9AY01715A |x Verlag |x Resolving-System |3 Volltext |
| 856 | 4 | 0 | |u https://pubs.rsc.org/en/content/articlelanding/2019/ay/c9ay01715a |x Verlag |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20200110 | ||
| 993 | |a Article | ||
| 994 | |a 2019 | ||
| 998 | |g 1034228889 |a Burhenne, Jürgen |m 1034228889:Burhenne, Jürgen |d 910000 |d 910100 |e 910000PB1034228889 |e 910100PB1034228889 |k 0/910000/ |k 1/910000/910100/ | ||
| 998 | |g 110903137 |a Mikus, Gerd |m 110903137:Mikus, Gerd |d 910000 |d 910100 |e 910000PM110903137 |e 910100PM110903137 |k 0/910000/ |k 1/910000/910100/ | ||
| 998 | |g 1060738538 |a Skopp, Gisela |m 1060738538:Skopp, Gisela |d 910000 |d 912100 |e 910000PS1060738538 |e 912100PS1060738538 |k 0/910000/ |k 1/910000/912100/ | ||
| 998 | |g 1181123127 |a Vay, Manuela |m 1181123127:Vay, Manuela |d 50000 |e 50000PV1181123127 |k 0/50000/ |p 1 |x j | ||
| 999 | |a KXP-PPN1687134588 |e 3574101597 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"person":[{"given":"Manuela","role":"aut","roleDisplay":"VerfasserIn","family":"Vay","display":"Vay, Manuela"},{"roleDisplay":"VerfasserIn","family":"Skopp","display":"Skopp, Gisela","given":"Gisela","role":"aut"},{"role":"aut","given":"Gerd","family":"Mikus","display":"Mikus, Gerd","roleDisplay":"VerfasserIn"},{"display":"Burhenne, Jürgen","family":"Burhenne","roleDisplay":"VerfasserIn","role":"aut","given":"Jürgen"}],"title":[{"title":"Simultaneous quantification of the CYP2D6 substrate yohimbine, its metabolite 11-OH-yohimbine, and the CYP2D6 inhibitor paroxetine in human plasma","title_sort":"Simultaneous quantification of the CYP2D6 substrate yohimbine, its metabolite 11-OH-yohimbine, and the CYP2D6 inhibitor paroxetine in human plasma"}],"note":["Gesehen am 10.01.2019"],"type":{"media":"Online-Ressource","bibl":"article-journal"},"physDesc":[{"extent":"8 S."}],"id":{"eki":["1687134588"],"doi":["10.1039/C9AY01715A"]},"language":["eng"],"recId":"1687134588","relHost":[{"recId":"609401521","physDesc":[{"extent":"Online-Ressource"}],"language":["eng"],"id":{"eki":["609401521"],"issn":["1759-9679"],"zdb":["2515210-5"]},"type":{"media":"Online-Ressource","bibl":"periodical"},"title":[{"title":"Analytical methods","title_sort":"Analytical methods"}],"note":["Gesehen am 20.02.2024","Fortsetzung der Druck-Ausgabe"],"disp":"Simultaneous quantification of the CYP2D6 substrate yohimbine, its metabolite 11-OH-yohimbine, and the CYP2D6 inhibitor paroxetine in human plasmaAnalytical methods","pubHistory":["1.2009 -"],"origin":[{"dateIssuedDisp":"2009-","publisher":"RSC Publ.","dateIssuedKey":"2009","publisherPlace":"Cambridge"}],"part":{"issue":"47","extent":"8","text":"11(2019), 47, Seite 5976-5983","year":"2019","pages":"5976-5983","volume":"11"},"name":{"displayForm":["Royal Society of Chemistry"]}}],"name":{"displayForm":["Manuela Vay, Gisela Skopp, Gerd Mikus and Jürgen Burhenne"]},"origin":[{"dateIssuedKey":"2019","dateIssuedDisp":"4 November 2019"}]} | ||
| SRT | |a VAYMANUELASIMULTANEO4201 | ||